Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M18.5Revenue (TTM) $M15.0Net Margin (%)-73.7Altman Z-Score-16.0
Enterprise Value $M-6.4EPS (TTM) $-3.1Operating Margin %-93.7Piotroski F-Score4
P/E(ttm)--Beneish M-Score3.1Pre-tax Margin (%)-73.6Higher ROA y-yY
Price/Book2.010-y EBITDA Growth Rate %--Quick Ratio3.1Cash flow > EarningsN
Price/Sales0.55-y EBITDA Growth Rate %--Current Ratio3.1Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-48.7Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-185.2Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M6.8ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with ONTX

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ONTXGeorge Soros 2014-09-30 Sold Out $43 - $56.4
($50.59)
$ 2.74-95%Sold Out0
ONTXGeorge Soros 2014-06-30 Buy $41.8 - $63.4
($52.63)
$ 2.74-95%New holding108
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ONTX is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


ONTX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Michael & Jane Hoffman 2013 De10% Owner 2014-02-21Buy14,348$84.7-96.77view
Hoffman Michael BDirector, 10% Owner 2014-02-21Buy14,348$84.7-96.77view
Kumar RameshPresident and CEO 2014-02-10Sell3,354$150.7-98.18view
Kumar RameshPresident and CEO 2014-02-03Sell6,000$150.5-98.18view
Hoffman Michael BDirector, 10% Owner 2014-01-27Buy5,730$119.2-97.7view
Michael & Jane Hoffman 2013 De10% Owner 2014-01-27Buy5,730$119.2-97.7view
Michael & Jane Hoffman 2013 De10% Owner 2013-11-22Buy500$143.9-98.1view
Hoffman Michael BDirector, 10% Owner 2013-11-22Buy500$143.9-98.1view
Reddy E PremkumarDirector 2013-11-18Buy500$121-97.74view
Hoffman Michael BDirector, 10% Owner 2013-11-18Buy500$118.7-97.69view

Quarterly/Annual Reports about ONTX:

    News about ONTX:

    Articles On GuruFocus.com
    Weekly 3-Year Low Highlights: VCRA, CLUB, ARGS, ONTX, BOTA Jun 08 2014 

    More From Other Websites
    SeeThruEquity Initiates Coverage on Onconova Therapeutics, Inc. (NASDAQ: ONTX) with a Price Target... Jan 12 2017
    Onconova Therapeutics, Inc. Discusses Target Indications and Clinical Development in New SNNLive... Jan 10 2017
    Onconova Therapeutics, Inc. to Present Corporate Overview at Biotech Showcase 2017 Jan 05 2017
    ONCONOVA THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers Dec 15 2016
    Onconova and Cellworks Announce Presentation of Rigosertib Predictive Signature for Clinical... Dec 06 2016
    ONCONOVA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement,... Dec 05 2016
    Onconova Presents Phase 2 Data from Oral Rigosertib and Azacitidine Combination Trial in Higher-Risk... Dec 05 2016
    ONCONOVA THERAPEUTICS, INC. Financials Nov 23 2016
    Onconova Therapeutics, Inc. :ONTX-US: Earnings Analysis: Q3, 2016 By the Numbers : November 21, 2016 Nov 21 2016
    ONCONOVA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Nov 14 2016
    Onconova Therapeutics, Inc. Reports Recent Business Highlights and Third Quarter 2016 Financial... Nov 14 2016
    Onconova Therapeutics, Inc. Reports Recent Business Highlights and Third Quarter 2016 Financial... Nov 14 2016
    Onconova Announces Presentations Related to Rigosertib Clinical Studies in Myelodysplastic Syndromes... Nov 04 2016
    Onconova to Host Key Opinion Leader Luncheon on Novel Approaches to Targeting the RAS Pathway in... Oct 10 2016
    ONCONOVA THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Sep 27 2016
    ETF’s with exposure to Onconova Therapeutics, Inc. : September 27, 2016 Sep 27 2016
    Onconova Therapeutics, Inc. to Present Corporate Updates at Upcoming Investor Conferences Sep 07 2016
    ONCONOVA THERAPEUTICS, INC. Files SEC form 8-K, Costs Associated with Exit or Disposal Activities,... Aug 30 2016
    ETF’s with exposure to Onconova Therapeutics, Inc. : August 30, 2016 Aug 30 2016
    ETF’s with exposure to Onconova Therapeutics, Inc. : August 19, 2016 Aug 19 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)